AbbVie Signs a Worldwide License Agreement with Jacobio to Advance SHP2 Inhibitors
Shots:
- AbbVie to get an exclusive global license to develop and commercialize JAB-3068 and JAB-3312 from Jacobio
- AbbVie will provide undisclosed R&D cost to Jacobio for conducting early global CTs of JAB-3068 and JAB-3312. In addition- Jacobio has an exclusive option before registration trial initiation to develop and commercialize the SHP2 program in mainland China- Hong Kong- and Macau
- JAB-3068 and JAB-3312- are oral small molecules to inhibit SHP2 activity- a protein mediator of cellular signaling through RAS/MAP kinase pathway for the treatment of cancer
Ref: PRNewswire | Image: AbbVie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
